Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 13, 2013 - Issue 9
Submit an article Journal homepage
336
Views
17
CrossRef citations to date
0
Altmetric
Drug Profiles

The use of methylphenidate hydrochloride extended-release oral suspension for the treatment of ADHD

Ann ChildressCenter for Psychiatry and Behavioral Medicine, Inc., 7351 Prairie Falcon Road, Suite 160, Las Vegas, NV 89128, USACorrespondence[email protected]
&
Floyd R SalleeUniversity of Cincinnati, 260 Stetson Street, Suite 3200, Cincinnati, OH 45219, USA
Pages 979-988 | Published online: 09 Jan 2014

References

  • Visser SN, Bitsko RH, Danielson ML et al. Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children – United States, 2003 and 2007. MMWR 59(44), 1439–1443 (2010).
  • American Psychiatric Association; Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. American Psychiatric Association, Washington, DC, USA (2000).
  • Strine TW, Lesesne CA, Okoro CA et al. Emotional and behavioral difficulties and impairments in everyday functioning among children with a history of attention-deficit/hyperactivity disorder. Prev. Chronic. Dis. 3(2), A52 (2006).
  • Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am. J. Psychiatry 164(6), 942–948 (2007).
  • Fayyad J, De Graaf R, Kessler R et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br. J. Psychiatry 190, 402–409 (2007).
  • Doshi JA, Hodgkins P, Kahle J et al. Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. J. Am. Acad. Child Adolesc. Psychiatry 51(10), 990–1002 e1002 (2012).
  • Kessler RC, Green JG, Adler LA et al. Structure and diagnosis of adult attention-deficit/hyperactivity disorder: analysis of expanded symptom criteria from the Adult ADHD Clinical Diagnostic Scale. Arch. Gen. Psychiatry 67(11), 1168–1178 (2010).
  • Kessler RC, Adler L, Barkley R et al. Patterns and predictors of ADHD persistence into adulthood: results from the national comorbidity survey replication. Biol. Psychiatry 57(11), 1442–1451 (2005).
  • Klein RG, Mannuzza S, Olazagasti MA et al. Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. Arch. Gen. Psychiatry 69(12), 1295–1303 (2012).
  • Shaw M, Hodgkins P, Caci H et al. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med. 10, 99 (2012).
  • Lichtenstein P, Halldner L, Zetterqvist J et al. Medication for attention deficit-hyperactivity disorder and criminality. N. Engl. J. Med. 367(21), 2006–2014 (2012).
  • Arnsten AF, Rubia K. Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: disruptions in neurodevelopmental psychiatric disorders. J. Am. Acad. Child Adolesc. Psychiatry 51(4), 356–367 (2012).
  • Wolraich M, Brown L, Brown RT et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 128(5), 1007–1022 (2011).
  • Bradley C. The behavior of children receiving benzedrine. Am. J. Psychiatry 94, 577–585 (1937).
  • Ritalin®, Ritalin-SR®, package insert. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Pelham WEJr, Sturges J, Hoza J et al. Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder. Pediatrics 80(4), 491–501 (1987).
  • Armstrong RB, Damaraju CV, Ascher S, Schwarzman L, O'Neill J, Starr HL. Time course of treatment effect of OROS(R) methylphenidate in children with ADHD. J. Atten. Disord. 16(8), 697–705 (2012).
  • CONCERTA®, (methylphenidate HCl) package insert. McNeil Pediatrics, Division of Ortho-McNeil-Janssen Pharmaceuticals Inc., Titusville, NJ, USA (2013).
  • Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can. J. Clin. Pharmacol. 13(1), e50–e62 (2006).
  • Ritalin LA®, package insert. Novartis Pharmaceuticals Corporation East Hanover, NJ, USA.
  • Metadate CD®, package insert. UCB Inc., Smyrna, GA, USA.
  • Brams M, Mao AR, Doyle RL. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder. Postgrad. Med. 120(3), 69–88 (2008).
  • Swanson JM, Wigal SB, Wigal T et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 113(3 Pt 1), e206–e216 (2004).
  • Focalin XR®, package insert. Novartis Pharmaceuticals Corporation East Hanover, NJ, USA.
  • Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ. Mechanism of action of methylphenidate: insights from PET imaging studies. J. Atten. Disord. 6( Suppl. 1), S31–S43 (2002).
  • DAYTRANA®, prescribing information. Pharmaceuticals, Inc., MI, USA (2013).
  • Wilens TE, Boellner SW, Lopez FA et al. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry. 47(6), 700–708 (2008).
  • McGough JJ, Wigal SB, Abikoff H, Turnbow JM, Posner K, Moon E. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J. Atten. Disord. 9(3), 476–485 (2006).
  • Hansen DL, Tulinius D, Hansen EH. Adolescents' struggles with swallowing tablets: barriers, strategies and learning. Pharm. World Sci. 30(1), 65–69 (2008).
  • Polaha J, Dalton WT3rd, Lancaster BM. Parental report of medication acceptance among youth: implications for everyday practice. South. Med. J. 101(11), 1106–1112 (2008).
  • Meltzer EO, Welch MJ, Ostrom NK. Pill swallowing ability and training in children 6 to 11 years of age. Clin. Pediatr. (Phila) 45(8), 725–733 (2006).
  • Quillivant XR™, package insert. NextWave Pharmaceuticals Inc., CA, USA (2013).
  • Guo X, Chang RK, Hussain MA. Ion-exchange resins as drug delivery carriers. J. Pharm. Sci. 98(11), 3886–3902 (2009).
  • Childress AC, Berry SA. The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. Postgrad. Med. 122(5), 35–41 (2010).
  • Childress AC, Sallee FR, Berry SA. Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD. Postgrad. Med. 123(5), 80–88 (2011).
  • Wigal SB, Childress AC, Belden HW, Berry SA. NWP06, an extended release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study. J. Child Adolesc. Psychopharmacol. 23(1), 3–10 (2013).
  • Wigal SB, Gupta S, Guinta D, Swanson JM. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol. Bull. 34(1), 47–53 (1998).
  • Westover AN, Halm EA. Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review. BMC Cardiovasc. Disord. 12, 41 (2012).
  • Zosel A, Bartelson BB, Bailey E, Lowenstein S, Dart R. Characterization of adolescent prescription drug abuse and misuse using the Researched Abuse Diversion and Addiction-Related Surveillance (RADARS((R))) System. J. Am. Acad. Child Adolesc. Psychiatry. 52(2), 196–204 e192 (2013).
  • Parasrampuria DA, Schoedel KA, Schuller R et al. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users. J. Clin. Psychopharmacol. 27(5), 459–467 (2007).
  • Schachar R, Ickowicz A, Crosbie J et al. Cognitive and behavioral effects of multilayer-release methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 18(1), 11–24 (2008).
  • Jin L, Xu W, Kielbasa W et al. Safety and efficacy of LY2216684 in an open-label study in pediatric patients with attention-deficit/hyperactivity disorder. Presented at: The American Academy of Child and Adolescent Psychiatry 57th Annual Meeting. New York, NY, USA, 26–31 October 2010.
  • Findling RL, McNamara NK, Stansbrey RJ et al. A pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit/hyperactivity disorder combined type. J. Child Adolesc. Psychopharmacol. 17(1), 19–33 (2007).
  • Surman CB, Hammerness PG, Petty C et al. A pilot open label prospective study of memantine monotherapy in adults with ADHD. World J. Biol. Psychiatry 14(4), 291–298 (2013).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.